Skip to main content

Peptide Profile

Cortagen

vascular peptide bioregulator · cardiovascular Khavinson peptide · vessel cytomax

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a…

Longevity & CellularNot EvaluatedResearch Only
Routes
oral, subcutaneous

Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.

Educational research tools — not medical advice.

Overview

What Cortagen is

About Cortagen

Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms; microarray analysis demonstrates broad transcriptional effects following administration.

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a Khavinson-class bioregulator, cortagen is proposed to modulate transcriptional activity in aging target tissue by interacting with gene regulatory elements; microarray analysis of cardiac gene expression following cortagen administration has demonstrated broad effects on transcriptional profiles across multiple functional gene categories, suggesting tissue-regulatory activity beyond its cortical tissue origin. Published research on Khavinson-class peptides has further characterized the systematic gene expression regulatory potential of short bioregulator peptides across tissue types, providing the mechanistic context within which cortagen's transcriptional effects are interpreted. Cortagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives from Khavinson-series preclinical studies with no independent clinical trials published in Western-indexed journals. Cortagen benefits investigated in preclinical research include neuroprotective effects in neural tissue, cardiovascular gene expression modulation, and support for vascular wall integrity in aged animal models. As a brain cortex-derived Khavinson bioregulator, cortagen is proposed to regulate transcription in neural and cardiac tissue through chromatin-level mechanisms, potentially preserving tissue-specific gene expression patterns that decline with aging. Research interest encompasses cortagen's role in neurological aging, post-ischemic brain tissue recovery in preclinical models, and combined bioregulator protocols that pair cortagen with cardiovascular and metabolic peptides for comprehensive longevity applications. Cortagen is a research compound with no regulatory approval in any jurisdiction; evidence is limited to preclinical studies and Russian clinical research literature, with no independent randomized trials published in Western peer-reviewed journals.

Cortagen Benefits & Research Areas

neuroprotectiongene expression regulationLongevityanti-aging
The Research

What the evidence says about Cortagen

Research Evidence

Preclinical

based on 2 studies · most recent 2021

Regulatory Status

Availability Status
Research Only
FDA Status
Not Evaluated

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

2 sources cited · 1 moderate · 1 weak

1 Review · 1 Animal

  • Peptide Regulation of Gene Expression: A Systematic Review

    Molecules · 2021

    This systematic review documents the gene expression regulatory mechanisms of short peptides including cortagen, showing chromatin binding and epigenetic modulation in target cardiovascular tissues, consistent with cortagen's proposed cardioprotective and longevity-promoting profile.

    ReviewModeratePMID 34834147
  • The effect of short peptides on the expression of genes in the cardiac muscle of old male rats

    Neuroendocrinology Letters · 2004

    Research using cDNA microarray analysis found that cortagen altered expression across 110 cardiac gene categories in aged male rats, including genes involved in oxidative stress defense, energy metabolism, and structural remodeling, suggesting a broad transcriptional regulatory role in cardiac aging comparable to other Khavinson peptides.

    AnimalWeakPMID 15159690

Cortagen Side Effects & Safety Considerations

Research-use compound with limited human data. Evidence strength varies — see the Evidence section.

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Frequently Asked Questions — Cortagen

Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) classified as a Khavinson-class bioregulator derived from cerebral cortex tissue, investigated for gene expression regulatory effects in neural and cardiac tissue. As a Khavinson-class bioregulator, cortagen is proposed to modulate transcriptional activity in aging target tissue by interacting with gene regulatory elements; microarray analysis of cardiac gene expression following cortagen administration has demonstrated broad effects on transcriptional profiles across multiple functional gene categories, suggesting tissue-regulatory activity beyond its cortical tissue origin.

neuroprotection, gene expression regulation, Longevity, anti-aging.

Research on Cortagen primarily documents effects related to neuroprotection and gene expression regulation and Longevity and anti-aging. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Cortagen, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Cortagen is tracked across 2 research vendors on PeptideBase, with per-mg prices ranging $2.50–$2.84. This reflects research-use vendor pricing, not clinical or prescription costs.

This systematic review documents the gene expression regulatory mechanisms of short peptides including cortagen, showing chromatin binding and epigenetic modulation in target cardiovascular tissues, consistent with cortagen's proposed cardioprotective and longevity-promoting profile.

Access

How to get Cortagen

Market Pricing

2 vendors
$2.50/mgBudget
$2.50/mgMedian
$2.84/mgPremium
$2.50
$2.50
$2.84

Price per mg varies by quantity, vendor type, and formulation. Research use only.

Data verified July 2026 · Cortagen price intelligence

Where to buy Cortagen

Coverage expanding

No verified providers currently list Cortagen. Get notified when one does, or explore providers carrying similar peptides in the Longevity category.

Questions to ask your provider

Stay updated on verified Cortagen providers

New verified providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Last updated

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.